Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages i23-i30

  Mohammad, Aladdin J ^a,b   Weiner, Maria ^c   Sjöwall, Christopher ^c   Johansson, Martin E ^d   Bengtsson, Anders A ^a   Ståhl Hallengren, Christina ^e   Nived, Ola ^a   Eriksson, Per ^c   Sturfelt, Gunnar ^a   Segelmark, Mårten ^c  

^a LUND UNIVERSITY   (Sweden)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c LINKÖPING UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e HELSINGBORG HOSPITAL   (Sweden)

Author keywords

ANCA; end stage renal disease; incidence; lupus nephritis; systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADOLESCENT; ADULT; ANCA ASSOCIATED VASCULITIS; ANTI NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED NEPHRITIS; ARTICLE; CHILD; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; END STAGE RENAL DISEASE; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; INFANT; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PRIORITY JOURNAL; SURVIVAL RATE; SWEDEN; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BLOOD; COMPARATIVE STUDY; COMPLICATION; GLOMERULONEPHRITIS; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FEMALE; GLOMERULONEPHRITIS; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SWEDEN;

EID: 84926615279     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu396     Document Type: Article

References (34)

1. Savage CO. Pathogenesis of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Clin Exp Immunol 2011; 164 (Suppl 1): 23-26
2. Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol 2012; 24: 651-657
3. Houssiau FA, Lauwerys BR. Current management of lupus nephritis. Best Pract Res Clin Rheumatol 2013; 27: 319-328
4. Borchers AT, Leibushor N, Naguwa SM et al. Lupus nephritis: a critical review. Autoimmun Rev 2012; 12: 174-194
5. Stahl-Hallengren C, Jonsen A, Nived O et al. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000; 27: 685-691
6. Eilertsen GO, Fismen S, Hanssen TA et al. Decreased incidence of lupus nephritis in northern Norway is linked to increased use of antihypertensive and anticoagulant therapy. Nephrol Dial Transplant 2011; 26: 620-627
7. Statistics Sweden. http://www.scb.se (January 2014, date last accessed)
8. Jonsson H, Nived O, Sturfelt G et al. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol 1990; 29: 185-188
9. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277
10. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530
11. Mohammad AJ, Jacobsson LT, Mahr AD et al. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007; 46: 1329-1337
12. Mohammad AJ, Jacobsson LT, Westman KW et al. Incidence and survival rates inWegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 2009; 48: 1560-1565
13. Watts R, Lane S, Hanslik T et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222-227
14. Frodlund M, Dahlstrom O, Kastbom A et al. Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. BMJ Open 2013; 3: e003608
15. Eriksson P, Jacobsson L, Lindell A et al. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 2009; 265: 496-506
16. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994; 87: 671-678
17. Lam GK, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005; 23(5 Suppl 39): S120-S132
18. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
19. Yee CS, Gordon C, Dostal C et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004; 63: 525-529
20. de Groot K, Harper L, Jayne DR et al. Pulse Versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-680
21. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibodypositive vasculitis successfully treated with rituximab. J Intern Med 2005; 257: 540-548
22. Fujimoto S, Uezono S, Hisanaga S et al. Incidence of ANCAassociated primary renal vasculitis in the Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 2006; 1: 1016-1022
23. Watts RA, Scott DG, Jayne DR et al. Renal vasculitis in Japan and the UK-are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 2008; 23: 3928-3931
24. Patel M, Clarke AM, Bruce IN et al. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum 2006; 54: 2963-2969
25. Swaminathan S, Leung N, Lager DJ et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol 2006; 1: 483-487
26. Brugos B, Kiss E, Szodoray P et al. Retrospective analysis of patients with lupus nephritis: data from a large clinical immunological center in Hungary. Scand J Immunol 2006; 64: 433-437
27. Bastian HM, Roseman JM, McGwin G, Jr et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11: 152-160
28. Seligman VA, Lum RF, Olson JL et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am JMed 2002; 112: 726-729
29. Burgos PI, McGwin G, Jr, Pons-Estel GJ et al. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis 2011; 70: 393-394
30. Rihova Z, Jancova E, Merta M et al. Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press Res 2005; 28: 144-152
31. Hedger N, Stevens J, Drey N et al. Incidence and outcome of pauciimmune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study. Nephrol Dial Transplant 2000; 15: 1593-1599
32. Watanabe K, Tani Y, Kimura H et al. Clinical outcomes of Japanese MPOANCA-related nephritis: Significance of initial renal death for survival. Intern Med 2012; 51: 1969-1976
33. Ward MM. Changes in the incidence of end stage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009; 36: 63-67
34. Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-64